Clinical Trial Update: A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 biomarker-driven study evaluating MET and TP53 mutations in treatment-refractory squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN